🇺🇸 FDA
Pipeline program

TEV-48574 Dose Regimen A

TV48574-IMM-20038

Phase 2 small_molecule active

Quick answer

TEV-48574 Dose Regimen A for Crohn Disease is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Teva Pharma GmbH
Indication
Crohn Disease
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials